EUCTR2006-000844-17-SK进行中（未招募）1 期
A multi-centre pilot study of Rituximab in patients with active PsA
Vienna Medical University0 个研究点目标入组 30 人开始时间: 2009年9月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria
- •-Patients diagnosed with PsA according to the following criteria: Psoriasis or family history of psoriasis plus any one of the following criteria: clinical inflammatory enthesitis, radiographic enthesitis, distal interphalangeal joint disease, sacroiliitis or spinal inflammation, uncommon arthropathies (SAPHO, spondylodiscitis, arthritis mutilans, onchyo-pachydermo-periostitis, chronic multifocal recurrent osteomyelitis), dactylitis, monoarthritis, oligoarthritis (four or less swollen joints) (7)
- •-Age = 18 years
- •-Negative rheumatoid factor
- •-The disease should at least have been diagnosed 6 months prior to screening
- •-Active disease at the time of screening as defined by
- •o2 out of the following 3 criteria:
- •?= 4 swollen on a 66/68 joint count
- •?= 4 tender joints on a 66/68 joint count
- •?Presence of dactylitis
- •oand 1 out of the following 2 categories
- •?ESR = 28 mm/ h
- •?CRP = 1.5 mg/ dl
- •-Failure of a least one DMARD, namely MTX or Leflunomide
- •-If patients are using one DMARD, the DMARD must be at a stable dose for at least 4 weeks prior to screening.
- •-Patients on MTX must be receiving concurrent therapeutic folic acid.
- •-Patients using oral corticosteroids must have been on a stable dose of = 10 mg/ day for 2 weeks prior to screening. If using NSAIDs, patients must be on a stable dose for two weeks prior to screening.
- •-Women and men of childbearing potential must be using adequate birth control measures and should continue such precautions for six months after the last infusion of Rituximab.
- •-The screening laboratory test must meet the following criteria:
- •oHemoglobin = 8.5 g/ dl providing the low hemoglobin level is not due to other diseases than anemia of chronic inflammation.
- •oWBC = 3500 / µl
- •oNeutrophils = 1500 / µl
- •oPlatelets = 100 000 / µl
- •oSerum transaminase = 2 times the upper limit of normal
- •oSerum creatinine = 1.7 mg/ dl
- •-The patient must be able to adhere the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria
- •Patients are excluded if they meet one of the following criteria:
- •-Pregnant women, nursing mothers or a planned pregnancy within six months after last scheduled treatment
- •-Patients with other inflammatory diseases that might interfere with the evaluation of the psoriatic arthritis.
- •-Patients with fibromyalgia syndrome
- •-Use of Rituximab prior to screening
- •-Use of IM, IV, IA, cortocisteroids within 4 weeks prior to screening
- •-Treatment with any investigational drug within 3 months prior to screening
- •-Use of cyclosporine or tacrolimus within 4 weeks prior to screening
- •-A history of known allergy to murine proteins, e.g. allergy to Infliximab
- •-History of infected joint prosthesis within the previous 5 years
- •-Chronic infections
- •-History of active tuberculosis requiring treatment within the previous 3 years, or history of opportunistic infections within 2 months, uncontrolled active infection or documented HIV infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis without documented adequate therapy if they will not be treated according to the local TB guidelines.
- •-Current signs or symptoms of other severe uncontrolled disease which in the investigators opinion would put the patient at an unacceptable risk.
- •-History of lymphoproliferative disease, any current malignancies or history of malignancy within 5 years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin
- •-History of drug abuse
- •->75 years
研究者
相似试验
进行中（未招募）
不适用
Pilot study to evaluate the effect of Rituximab in combination with MTX in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by magnetic resonance imaging (MRI) in the hand of patients with rheumatoid arthritis. - NDMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2007-001754-11-ITROCHE
进行中（未招募）
1 期
Multicenter study of phase II with Rituximab, cyclophosphamide, doxorubicin liposomal (Myocet), vincristine, Prednisone, (R-COMP) in diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopathic patient - HEART01Diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopathic patientMedDRA version: 9.1Level: PTClassification code 10012818EUCTR2009-012143-42-ITIIL INTERGRUPPO ITALIANO LINFOMI ONLUS50
已完成
不适用
Phase II study of Rituximab in Patients with Systemic Lupus ErythematosusSystemic lupus erythematosusJPRN-UMIN000000762Zenyaku Kogyo Co., Ltd.70
进行中（未招募）
不适用
A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hypMedDRA version: 14.1Level: PTClassification code 10018372Term: Glomerulonephritis membranousSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-006115-59-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
已完成
不适用
ncontrolled trial of Rituximab treatment on refractory or steroid dependent nephrotic syndrome in adult.refractory or steroid dependent nephrotic syndromeJPRN-UMIN000014355Saitama Medical University Department of Nephrology5